Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239341 | 0.95 | LMNA (0.31) | LMNAL3MBTL1TDP1 | |
| SCHEMBL31386724 | 0.86 | LMNA (0.32) | LMNAL3MBTL1TDP1 | |
| SCHEMBL234252 | 0.84 | LMNA (0.36) | LMNAL3MBTL1TDP1AKR1B1KDM4E | |
| SCHEMBL2559273 | 0.83 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL6256241 | 0.83 | LMNA (0.32) | LMNAL3MBTL1TDP1 | |
| SCHEMBL999357 | 0.81 | ALDH1A1 (0.35) | LMNAL3MBTL1TDP1 | |
| SCHEMBL4338288 | 0.80 | LMNA (0.36) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL2558960 | 0.80 | LMNA (0.36) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL6087524 | 0.80 | LMNA (0.36) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL15966786 | 0.79 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1013 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790155-A | Threose nucleic acid antisense oligonucleotide and method thereof | 豪夫迈·罗氏有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-114025805-B | Method for preparing protein-oligonucleotide complex | 达因疗法公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119185345-A | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | 渤健马萨诸塞州股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118987017-A | Compositions and methods for treating and preventing amyotrophic lateral sclerosis | 渤健马萨诸塞州股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118434860-A | Threose nucleic acid antisense oligonucleotide and method thereof | 豪夫迈·罗氏有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-118339292-A | Antisense inhibitors of MIR17HG precursor RNAs as cancer therapeutics | 丹娜-法伯癌症研究院 | 2024-07-12 | — | — | CN | claimed |
| US-20240229042-A1 | COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | US | claimed |
| EP-4220360-B1 | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | HOFFMANN LA ROCHE (CH) | 2024-06-26 | — | — | EP | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20240182903-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BIOGEN MA INC (US) | 2024-06-06 | — | — | US | claimed |
| EP-1601789-A4 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | IDERA PHARMACEUTICALS INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-7276489-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| EP-1601789-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | HYBRIDON, INC. (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2004-10-07 | — | — | US | claimed |
| WO-2004064782-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | HYBRIDON, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2003057822-A9 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | HYBRIDON, INC. | 2004-05-20 | — | — | US | claimed |
| EP-1393745-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends | HYBRIDON, INC. (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2003057822-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| WO-2003035836-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC. (US) | 2003-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182903-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SOD1, SMN1; SMN2, SOD3 | LMNA 801/4885L3MBTL1 261/4885TDP1 53/4885 |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, TLR5 | LMNA 4834/4885L3MBTL1 2327/4885TDP1 410/4885 |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, ENTPD5 | LMNA 4649/4885L3MBTL1 1024/4885TDP1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.